CLEANER Vac® Thrombectomy System Expands into Europe Following Successful U.S. Launch

Plano, Texas — Argon Medical Devices has begun commercial sales of its CLEANER Vac® Thrombectomy System in Europe upon receiving their CE Mark certification.  This marks a significant milestone in the global expansion of the company’s venous intervention portfolio.

Originally launched in the U.S. in September 2024, CLEANER Vac® was introduced as a next-generation solution for removing blood clots, or thrombus, from the peripheral venous vasculature. The expansion into Europe reflects growing international demand for mechanical thrombectomy technologies, particularly as clinicians seek alternatives to traditional treatments such as anticoagulation and thrombolytic therapy.

“With the introduction of CLEANER Vac® in Europe, we are continuing to expand access to innovative, minimally invasive solutions that address the evolving needs of physicians and patients worldwide,” said George Leondis, President and Chief Executive Officer of Argon Medical. “Building on the strong momentum of our U.S. launch, this milestone reinforces our commitment to advancing venous care through clinically driven innovation and global reach.”

The company’s international rollout represents a key step in scaling its innovation globally, building on the momentum established in the U.S. market and ongoing clinical research initiatives aimed at further evaluating device performance in conditions such as deep vein thrombosis.  “Just three months after launch, it’s encouraging to see CLEANER Vac gaining real momentum across Europe,” said Matthew Edwards Senior Vice President and General Manager of EMEA. “What stands out most is the strong belief from our teams, partners, and physicians, with early clinical use building confidence in real-world settings. While it’s still early, this is a strong start—and very much a team effort across Argon.”

As adoption grows, the CLEANER Vac® Thrombectomy System is expected to play an increasingly important role in modern venous care, offering clinicians a practical, controlled approach to clot removal and contributing to improved patient treatment options worldwide.